Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.
Immunohistochemistry
Periostin
Upper urinary tract
Urothelial carcinoma
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Jul 2022
18 Jul 2022
Historique:
received:
27
04
2022
accepted:
12
07
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
epublish
Résumé
Periostin is an extracellular matrix protein that has been known to be implicated in fibrillogenesis and cell migration, including cancer metastasis. Periostin overexpression in cancer cells and/or intervening stroma is usually related to tumor progression and poor patient outcomes in various human cancers; however, its role in urothelial carcinoma, especially upper urinary tract urothelial carcinomas (UTUCs), remains inconclusive. Samples from 126 consecutive cases of invasive UTUC (69 renal pelvic cancers and 57 ureteral cancers) were histologically reviewed and analyzed for periostin expression using immunohistochemistry. The intensities of immunoreactivity and the fraction of positive cancer cells and stroma (i.e., epithelial and stromal expression, respectively) were classified into four categories each (intensity, 0-3; fraction, 0-25% = 1; 26-50% = 2; 51-75% = 3; and > 75% = 4). The overall score was determined by multiplying both scores, and overall scores ≥ 6 were considered to indicate high periostin expression. Among 126 UTUCs, 55 (44%; 27 renal pelvic and 28 ureteral cancers) showed high stromal periostin expression. None of the cases were considered to have high epithelial periostin expression. High stromal periostin expression was associated with non-papillary gross findings, higher pathological T category, lymphovascular invasion, concomitant carcinoma in situ, subtype histology, lymph node metastasis, positive surgical margins, high tumor budding, and high tumor-associated immune cell status. Multivariate analysis revealed that high stromal periostin expression was an independent predictor of overall survival (p = 0.00072, hazard ratio = 3.62), and lymphovascular invasion and high stromal periostin expression were independent predictors of cancer-specific survival (p = 0.032 and 0.020, hazard ratio = 2.61 and 3.07, respectively). Stromal periostin expression was often observed in invasive UTUCs with adverse clinicopathological factors and may be a useful predictor of patient outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
Periostin is an extracellular matrix protein that has been known to be implicated in fibrillogenesis and cell migration, including cancer metastasis. Periostin overexpression in cancer cells and/or intervening stroma is usually related to tumor progression and poor patient outcomes in various human cancers; however, its role in urothelial carcinoma, especially upper urinary tract urothelial carcinomas (UTUCs), remains inconclusive.
METHODS
METHODS
Samples from 126 consecutive cases of invasive UTUC (69 renal pelvic cancers and 57 ureteral cancers) were histologically reviewed and analyzed for periostin expression using immunohistochemistry. The intensities of immunoreactivity and the fraction of positive cancer cells and stroma (i.e., epithelial and stromal expression, respectively) were classified into four categories each (intensity, 0-3; fraction, 0-25% = 1; 26-50% = 2; 51-75% = 3; and > 75% = 4). The overall score was determined by multiplying both scores, and overall scores ≥ 6 were considered to indicate high periostin expression.
RESULTS
RESULTS
Among 126 UTUCs, 55 (44%; 27 renal pelvic and 28 ureteral cancers) showed high stromal periostin expression. None of the cases were considered to have high epithelial periostin expression. High stromal periostin expression was associated with non-papillary gross findings, higher pathological T category, lymphovascular invasion, concomitant carcinoma in situ, subtype histology, lymph node metastasis, positive surgical margins, high tumor budding, and high tumor-associated immune cell status. Multivariate analysis revealed that high stromal periostin expression was an independent predictor of overall survival (p = 0.00072, hazard ratio = 3.62), and lymphovascular invasion and high stromal periostin expression were independent predictors of cancer-specific survival (p = 0.032 and 0.020, hazard ratio = 2.61 and 3.07, respectively).
CONCLUSIONS
CONCLUSIONS
Stromal periostin expression was often observed in invasive UTUCs with adverse clinicopathological factors and may be a useful predictor of patient outcomes.
Identifiants
pubmed: 35850759
doi: 10.1186/s12885-022-09893-7
pii: 10.1186/s12885-022-09893-7
pmc: PMC9290244
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
787Informations de copyright
© 2022. The Author(s).
Références
Clin Genitourin Cancer. 2018 Dec;16(6):e1257-e1265
pubmed: 30170989
Cell. 2011 Nov 23;147(5):992-1009
pubmed: 22118458
Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6871s-6s
pubmed: 18006792
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Eur J Intern Med. 2017 Mar;38:12-16
pubmed: 27939043
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530
Oncotarget. 2016 Apr 26;7(17):23335-45
pubmed: 26981774
Eur Urol Oncol. 2021 Sep 21;:
pubmed: 34561205
J Bone Miner Res. 1999 Jul;14(7):1239-49
pubmed: 10404027
J Pathol Transl Med. 2017 May;51(3):306-313
pubmed: 28407462
Onco Targets Ther. 2019 Sep 24;12:7725-7735
pubmed: 31576137
Cancers (Basel). 2021 Oct 11;13(20):
pubmed: 34680221
Clin Genitourin Cancer. 2013 Dec;11(4):537-44
pubmed: 23850551
Trends Pharmacol Sci. 2019 Jun;40(6):419-429
pubmed: 31078320
Front Oncol. 2018 Jun 12;8:225
pubmed: 29946533
BJU Int. 2012 Sep;110(5):674-81
pubmed: 22348322
Clin Genitourin Cancer. 2014 Oct;12(5):301-11
pubmed: 24656869
Oncoimmunology. 2021 Jan 4;10(1):1861737
pubmed: 33489471
BMC Cancer. 2010 Jun 09;10:273
pubmed: 20534149
Oncol Lett. 2021 Jun;21(6):445
pubmed: 33868483
J Clin Pathol. 2018 Feb;71(2):154-160
pubmed: 28768702
Eur Urol. 2012 Jul;62(1):100-14
pubmed: 22381168
Int J Cancer. 2005 Oct 20;117(1):51-8
pubmed: 15880581
Pathol Int. 2021 Mar;71(3):173-182
pubmed: 33503295
Allergy. 2021 Dec;76(12):3659-3686
pubmed: 34519063
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
Cancer Immunol Immunother. 2020 May;69(5):689-702
pubmed: 32030476
Virchows Arch. 2021 Jul;479(1):45-55
pubmed: 33404852
Int J Oncol. 2008 Jan;32(1):161-9
pubmed: 18097555
Am J Pathol. 2010 Jul;177(1):387-403
pubmed: 20489157
Int J Oncol. 2011 Jun;38(6):1759-66
pubmed: 21468544
Virchows Arch. 2021 Jun;478(6):1089-1097
pubmed: 33420835
Int J Mol Sci. 2019 Jan 04;20(1):
pubmed: 30621220
Nat Commun. 2019 Jul 5;10(1):2977
pubmed: 31278255
Cancer Lett. 2009 Aug 28;281(2):188-95
pubmed: 19321256
Cell Mol Life Sci. 2009 Jul;66(14):2219-30
pubmed: 19308325
Virchows Arch. 2011 Nov;459(5):465-75
pubmed: 21997759
Nature. 2011 Dec 07;481(7379):85-9
pubmed: 22158103
EMBO J. 2012 Jan 18;31(2):254-6
pubmed: 22179697
Eur Urol Oncol. 2021 Apr;4(2):170-179
pubmed: 33386276
Urology. 2017 Feb;100:9-15
pubmed: 27516121